A study analyzed the geographic and institutional disparities in clinical trial distribution for candidates targeting the ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after ...

With a range of treatments available for presbyopia, the challenge for clinicians is to guide patients toward the most ...

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss ...

A novel DIPN method enhances GA segmentation by integrating ConvLSTM, projection attention, adaptive pooling, and contrastive ...

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment ...

The US Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for ...

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

Researchers from the Czech Republic found that an AI system showed higher sensitivity and specificity for screening diabetic ...